TrialCancer chemotherapy and pharmacology2019

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Whitney P Kirschbrown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.